EIF2B4 and hepatocellular carcinoma: By bridging cell-intrinsic proliferation and microenvironmental immunosuppression, our work provides a framework for novel combination therapies and underscores the urgency of advancing EIF2B4-targeted strategies into clinical trials to address unmet needs in HCC treatment.